Tag: ATI-0918

April 30, 2018

Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

Cytori Therapeutics (Nasdaq:CYTX) provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product....
March 15, 2018

Top 10 Stem Cell Companies On The NASDAQ

The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021....
March 9, 2018

Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results

Cytori Therapeutics (NASDAQ:CYTX) announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical...
April 10, 2017

Cytori Announces Proposed Public Offering of Common Stock

Cytori Therapeutics announced it plans to offer a public offering of common stock in order to fund the HABEO and...